Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
Protocol ID
ACNS1821
Disease (Sub Disease)
Diffuse Intrinsic Pontine Glioma
Diagnosis Stage
Newly diagnosed
Location
QLD, NZ
Sponsor
National Cancer Institute (NCI)
Links
Trial Status
Open
Sites
Queensland Children's Hospital
Christchurch Hospital
Christchurch Hospital
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
12 Months to 21 Years
International registry ID's
NCT05099003
| Study Title | A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG) |
|---|---|
| Protocol ID | ACNS1821 |
| Disease (Sub Disease) | Diffuse Intrinsic Pontine Glioma |
| Diagnosis Stage | Newly diagnosed |
| Location | QLD / NZ |
| Sponsor | National Cancer Institute (NCI) |
| Links | https://clinicaltrials.gov/ct2/show/NCT05099003 |
| Trial Status | Open |
| Trial Open Date | 05/05/2022 |
| Sites | Queensland Children's Hospital / Christchurch Hospital |
| Study Type | Treatment |
| Phase | Phase 1/2 |
| Age Eligibility | 12 Months to 21 Years |
| International registry ID's | NCT05099003 |